Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRMA NASDAQ:LEXX NASDAQ:LPCN NASDAQ:SYBX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRMADermata Therapeutics$6.37-2.3%$6.83$5.74▼$28.80$4.16M0.5624,469 shs36,854 shsLEXXLexaria Bioscience$0.83-1.1%$0.93$0.79▼$4.38$16.41M0.79205,362 shs117,397 shsLPCNLipocine$2.98-1.3%$3.20$2.68▼$6.17$16.37M1.2439,608 shs16,223 shsSYBXSynlogic$1.36-1.4%$1.33$0.90▼$1.96$16.14M0.52101,821 shs2,820 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRMADermata Therapeutics-2.30%+2.21%+1.11%-21.40%-72.66%LEXXLexaria Bioscience-1.07%-7.78%-5.68%-23.15%-76.88%LPCNLipocine-1.32%-7.74%-5.10%-9.15%-40.87%SYBXSynlogic-1.38%-11.63%+14.36%+21.51%-17.02%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDRMADermata Therapeutics1.7102 of 5 stars3.53.00.00.01.10.80.0LEXXLexaria Bioscience2.6364 of 5 stars3.52.00.00.01.53.30.6LPCNLipocine2.8051 of 5 stars3.55.00.00.02.50.00.6SYBXSynlogic1.0006 of 5 stars0.05.00.00.00.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRMADermata Therapeutics 3.00Buy$30.00370.96% UpsideLEXXLexaria Bioscience 3.00Buy$4.00381.93% UpsideLPCNLipocine 3.00Buy$9.00202.01% UpsideSYBXSynlogic 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest DRMA, SYBX, LEXX, and LPCN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/29/2025LEXXLexaria BioscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $4.007/1/2025LEXXLexaria BioscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $5.006/27/2025LPCNLipocineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.006/10/2025LPCNLipocineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.005/29/2025LPCNLipocineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$8.005/21/2025DRMADermata TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$60.00 ➝ $30.00(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRMADermata TherapeuticsN/AN/AN/AN/A$6.20 per shareN/ALEXXLexaria Bioscience$460K35.29N/AN/A$0.48 per share1.73LPCNLipocine$11.20M1.44N/AN/A$3.16 per share0.94SYBXSynlogic$10K1,592.25N/AN/A$1.09 per share1.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRMADermata Therapeutics-$12.29M-$16.41N/A∞N/AN/A-270.81%-179.96%N/ALEXXLexaria Bioscience-$5.80M-$0.67N/AN/AN/A-1,849.19%-157.22%-133.69%N/ALPCNLipocine$10K-$1.02N/A∞N/AN/A-23.59%-21.91%N/ASYBXSynlogic-$23.36M-$2.51N/AN/AN/AN/A10.91%7.47%8/14/2025 (Estimated)Latest DRMA, SYBX, LEXX, and LPCN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025LPCNLipocine-$0.41N/AN/AN/A$0.23 millionN/A8/14/2025Q2 2025SYBXSynlogic-$0.13N/AN/AN/AN/AN/A8/5/2025Q2 2025LPCNLipocine-$0.41-$0.41N/A-$0.41$1.00 million$0.62 million7/14/2025Q3 2025LEXXLexaria Bioscience-$0.15-$0.21-$0.06-$0.21$0.17 million$0.17 million5/14/2025Q1 2025DRMADermata Therapeutics-$4.50-$4.50N/A-$0.45N/AN/A5/8/2025Q4 2024LPCNLipocine-$0.35-$0.35N/A-$0.35$0.35 million$0.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDRMADermata TherapeuticsN/AN/AN/AN/AN/ALEXXLexaria BioscienceN/AN/AN/AN/AN/ALPCNLipocineN/AN/AN/AN/AN/ASYBXSynlogicN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRMADermata TherapeuticsN/A3.703.70LEXXLexaria BioscienceN/A3.903.90LPCNLipocineN/A12.7115.64SYBXSynlogicN/A3.683.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRMADermata Therapeutics8.67%LEXXLexaria Bioscience13.06%LPCNLipocine9.11%SYBXSynlogic63.40%Insider OwnershipCompanyInsider OwnershipDRMADermata Therapeutics18.50%LEXXLexaria Bioscience26.40%LPCNLipocine6.35%SYBXSynlogic3.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRMADermata Therapeutics8638,000520,000Not OptionableLEXXLexaria Bioscience719.56 million14.40 millionNot OptionableLPCNLipocine105.42 million5.01 millionNo DataSYBXSynlogic8011.70 million11.34 millionOptionableDRMA, SYBX, LEXX, and LPCN HeadlinesRecent News About These CompaniesSynlogic (SYBX) Expected to Announce Quarterly Earnings on ThursdayAugust 7 at 2:46 AM | americanbankingnews.comSynlogic, Inc. (SYBX) Latest Stock News & Headlines - Yahoo FinanceJune 28, 2025 | finance.yahoo.comSynlogic's executive sells shares worth $2,802February 5, 2025 | msn.comSynlogic Reports Q3 2024 Financial OutcomesNovember 14, 2024 | markets.businessinsider.comSynlogic, Inc.: Synlogic Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | finanznachrichten.deSynlogic Reports Third Quarter 2024 Financial ResultsNovember 12, 2024 | globenewswire.comSynlogic preps phenylketonuria drug for phase 3 after mid-stage winNovember 6, 2024 | pharmaphorum.comPSynlogic, Inc. (0A8U.L)August 24, 2024 | nz.finance.yahoo.comMIN.SG,0P0001I7V6,0 (MIN.SG)August 16, 2024 | nz.finance.yahoo.comMaintaining Hold on Synlogic Amid Strategic Reassessment and Financial UncertaintyAugust 14, 2024 | markets.businessinsider.comSynlogic, Inc.: Synlogic Reports Second Quarter 2024 Financial ResultsAugust 8, 2024 | finanznachrichten.deSYBX Stock Earnings: Synlogic Beats EPS for Q2 2024August 8, 2024 | investorplace.comSynlogic Reports Second Quarter 2024 Financial ResultsAugust 8, 2024 | globenewswire.comSynlogic Inc.July 21, 2024 | wsj.comSynlogic Inc SYBXJuly 21, 2024 | morningstar.comMThe Summer Stock Exodus: 3 Companies to Ditch Before the Heat HitsMay 23, 2024 | investorplace.comHold Rating Maintained for Synlogic Amidst Setbacks and Financial UncertaintiesMay 16, 2024 | markets.businessinsider.comSYBX Stock Earnings: Synlogic Misses EPS, Misses Revenue for Q1 2024May 14, 2024 | investorplace.comSynlogic, Inc.: Synlogic Reports First Quarter 2024 Financial ResultsMay 14, 2024 | finanznachrichten.deSynlogic Flat on Q1 NumbersMay 14, 2024 | baystreet.caNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDRMA, SYBX, LEXX, and LPCN Company DescriptionsDermata Therapeutics NASDAQ:DRMA$6.37 -0.15 (-2.30%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$6.37 +0.00 (+0.02%) As of 08/7/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.Lexaria Bioscience NASDAQ:LEXX$0.83 -0.01 (-1.07%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$0.82 -0.01 (-0.84%) As of 08/7/2025 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.Lipocine NASDAQ:LPCN$2.98 -0.04 (-1.32%) Closing price 08/7/2025 03:58 PM EasternExtended Trading$3.05 +0.07 (+2.35%) As of 08/7/2025 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.Synlogic NASDAQ:SYBX$1.36 -0.02 (-1.38%) Closing price 08/7/2025 03:55 PM EasternExtended Trading$1.38 +0.02 (+1.77%) As of 08/7/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down Realty Income Rallies Post-Earnings Miss—Here’s What Drove It Don't Mix the Signal for Noise in Super Micro Computer's Earnings Microsoft Stock Gains as Analysts Boost Price Targets Joby Deal Gives Blade New Direction, But Stock Lacks Lift Uber Technologies Is Driving Cash Flow: Ride It Higher for Life How DigitalOcean's Focus Is Fueling Explosive Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
